Skip to main content
SpringerLink
Log in

Blood Substitutes for Surgery and Trauma

Efficacy and Toxicity Issues

  • Current Opinion
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Solutions of modified haemoglobin and perfluorocarbon emulsions are currently being tested in advanced human trials. Concerns about renal injury and hypertension with the haemoglobin solutions, and drug retention and pulmonary injury with the perfluorocarbons have been successfully addressed. However, newly recognised inflammatory toxicities of the haemoglobin solutions and the low oxygen-carrying capacity of the perfluorocarbons remain as potential limits on efficacy. As a result, the role of blood substitutes will be less than originally imagined, and none is likely to be licenced for use for several years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bolin RB, Geyer RP, Nemo GJ, editors. Advances in blood substitute research. New York (NY): Alan R. Liss, Inc., 1983 (Progress in Clinical and Biological Research; 122) Conferences

    Google Scholar 

  2. Hess JR, Winslow RM. Red cell substitutes. In: Anderson KC, Ness PM, editors. Scientific Basis of Transfusion Medicine. Philadelphia (PA): Saunders, 1994: 815–29

    Google Scholar 

  3. Eaton JW. Hemoglobin-based blood substitutes: a dream-like trade of blood and guile? J Lab Clin Med 1996 May; 127(5): 416–7

    Article  PubMed  CAS  Google Scholar 

  4. Naval Research Advisory Committee. Delivery of artificial blood to the military. Washington (WA): Office of the Assistant Secretary of the Navy (Research Development and Acquisition), 1992

    Google Scholar 

  5. Hess JR. Review of modified hemoglobin research at Letterman: attempts to delineate the toxicity of cell-free tetrameric hemoglobin. Artif Cells Blood Subs Immobil Biotech 1995; 23: 277–89

    Article  CAS  Google Scholar 

  6. Kaufman RJ. Clinical development of perfluorocarbon-based emulsions as red cell substitutes. In: Winslow RM, Vandegriff KD, Intaglietta M, editors. Blood substitutes: physiological basis of efficacy. Boston (MA): Birkhauser, 1995: 53–75

    Chapter  Google Scholar 

  7. Hess JR. Blood Substitutes. Sem Hem 1996 Oct; 33: 369–78

    CAS  Google Scholar 

  8. Hess JR. Alternative oxygen carriers. Cur Opin Hematol 1996 Nov; 3: 492–7

    Article  CAS  Google Scholar 

  9. Holden C. ScienceScope: drug industry faces towering R&D costs. Science 1998 May 22; 280: 1181

    Google Scholar 

  10. Hayes Jr AH. Safety considerations in product development. Drug Saf 1990; 5Suppl. 1: 24–6

    Article  PubMed  Google Scholar 

  11. U.S. Congress Office of Technology Assessment. Pharmaceutical R&D: costs, risks and rewards, OTA-H-522. Washington, DC (WA): U.S. Government Printing Office, Feburary 1993

    Google Scholar 

  12. Winslow RM. Hemoglobin-based red cell substitutes. Baltimore (MD): Johns Hopkins University Press, 1992

    Google Scholar 

  13. Amberson WR, Mulder AG, Steggerda FR, et al. Mammalian life without red corpuscles. Science 1933; 78: 106–7

    Article  PubMed  CAS  Google Scholar 

  14. Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1949; 1: 469–89

    PubMed  CAS  Google Scholar 

  15. Baldwin AL, Wilson LM, Valeski JE, et al. Ultrastructural effects of intravascularly injected polyethylene glycol-hemoglobin in intestinal mucosa. Am J Physio 1998; 275: H615–25

    CAS  Google Scholar 

  16. Kendrick DB. Blood Program in World War II. Washington, DC: Office of the Surgeon General, Department of the Army, 1964

    Google Scholar 

  17. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109–42

    PubMed  CAS  Google Scholar 

  18. Gulati A, Rebello S. Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. J Lab Clin Med 1994 Jul; 124(1): 125–33

    PubMed  CAS  Google Scholar 

  19. Schultz SC, Grady B, Cole F, et al. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 1993: 122: 301–8

    PubMed  CAS  Google Scholar 

  20. Lieberthal W, LaRaia J, Valeri CR. Role of thromboxane in mediating the intrarenal vasoconstriction induced by unmodified stroma free hemoglobin in the isolate perfused rat kidney, Biomat Artif Cell Immob Biotech 1992; 20: 663–7

    CAS  Google Scholar 

  21. Winslow RM, Gonzales A, Gonzales ML, et al. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J Appl Physiol 1998 Sep: 85(3): 993–1003

    PubMed  CAS  Google Scholar 

  22. Rohlfs RJ, Bruner E, Gonzales A, et al. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J Biol Chem. 1998 May 15; 273(20): 12128–34

    Article  PubMed  CAS  Google Scholar 

  23. Hess JR, Macdonald VW, Gomez CL, et al. Hypertension after hemoglbulin administration: the effects of cyanomethemoglobin. Blood 1992; 80(363a): 1441

    Google Scholar 

  24. Kasper S-M, Grune F, Walter M, et al. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998; 87: 284–91

    PubMed  CAS  Google Scholar 

  25. Biro GP, Ou C, Ryan-McFarlane C, et al. Oxyradical generation after resuscitation of hemorrhagic shock with blood or stroma-free hemoglobin solution. Artif Cells Blod Substit Immobil Biotechnol 1995; 23: 631–45

    Article  CAS  Google Scholar 

  26. Hess JR, Macdonald VW, Brinkley WW Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Applied Physiol 1993: 74: 1769–78

    CAS  Google Scholar 

  27. Nelson DJ. HemAssist TM: development and clinical profile. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 353–400

    Google Scholar 

  28. Siegel JH, Fabian M, Smith JA, et al. Human recombinant hemoglobin as a safe and effective mode of volume replacement in a large animal model of hemorrhagic, hypovolemic, oxygen debt shock. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 119–64

    Google Scholar 

  29. Panter SS, Regan RF. Interactions of hemoglobin with the central nervous system. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 219–34

    Google Scholar 

  30. Saxena R, Wijnhound AD, Carton H et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999; 30: 993–6

    Article  PubMed  CAS  Google Scholar 

  31. Smith DJ, Winslow RM. Effects of extraerythrocytic hemoglobin and its components on mononuclear cell procoagulant activity. J Lab Clin Med 1992; 119: 176–82

    PubMed  CAS  Google Scholar 

  32. McFaul SJ, Bowman PD, Villa VM, et al. Hemoglobin stimulates mononuclear leukocytes to release to release interleukin-8 and tumor necrosis factor alpha. Blood 1994; 84: 3175–81

    PubMed  CAS  Google Scholar 

  33. White CT, Murray AJ, Greene JR, et al. Toxicity of human hemoglobin infused into rabbits. J Lab Clin Med 1986; 108: 121–31

    PubMed  CAS  Google Scholar 

  34. Levin J, Roth RI. Interactions between hemoglobin and bacterial endotoxin in vitro and in vivo. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 235–62

    Google Scholar 

  35. Krishnamurti C, Carter AJ, Maglasang P, et al. Cardiovascular toxicity of human cross-linked hemoglobin in a rabbit endotoxemia model. Crit Care Med 1997 Nov; 25(11): 1874–80

    Article  PubMed  CAS  Google Scholar 

  36. Guidance for industry: efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers [draft — docket # 90N0349]. U.S. Food and Drug Administration, 1997 Sep 8: 4

  37. Burton TM. Baxter ends a U.S. blood-substitute trial. Wall Street J 1998 Apr 1: B8

    Google Scholar 

  38. Przybelski RJ, Daily EK, Stern KN, et al. A graded scale for assessment of safety of blood substitutes. Transfusion 1997 June; 37: 749–51

    Article  PubMed  CAS  Google Scholar 

  39. Cohn SM, Zeig PM, Rosenfield AT, et al. Resuscitation of pulmonary contusion: effects of a red cell substitute. Crit Care Med 1997; 25(3): 484–91

    Article  PubMed  CAS  Google Scholar 

  40. Reah G, Bodenham AR, Mallick A, et al. Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med 1997; 25(9): 1480–8

    Article  PubMed  CAS  Google Scholar 

  41. Gould SA, Sehgal LR, Moss GS, et al. The clinical development of human polymerized hemoglobin. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 401–19

    Google Scholar 

  42. Gould SA, Moore EE, Moore FA, et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma 1997; 43(2): 325–31

    Article  PubMed  CAS  Google Scholar 

  43. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187: 113–22

    Article  PubMed  CAS  Google Scholar 

  44. Mitchell J. Upjohn halts blood substitute product testing. Wall Street J 1991 Aprl 1: B4

    Google Scholar 

  45. Light RW, Jacobs EE, Rentko VT, et al. Use of HBOC-201 as an oxygen therapeutic in the preclinical and clinical settings. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 421–36

    Google Scholar 

  46. Kaspar S-M, Walter M, Grune, et al. Effects of hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996; 83: 921–7

    Google Scholar 

  47. Levy JH, Goodnough LT, Greilich P, et al. A room-temperature stable hemoglobin (HBOC-201) eliminates allogeneic red blood cell (RBC) transfusion in post-operative cardiac surgery patients [abstract #682]. Circulation 98: I-132

  48. Teicher BA, Dupuis NP, Liu F, et al. Administration of a hemoglobin solution decreases hypoxia and increases radiation response in a rat mammary adenocarcinoma. Dru Dev Res 1995; 34: 231–40

    Article  CAS  Google Scholar 

  49. Gonzales P, Hackney AC, Jones et al. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J Investig Med 1997 Jun; 45: 258–64

    Google Scholar 

  50. Adamson JG, Bonaventura BJ, Er SS, et al. Production, characterization and clinical evaluation of Hemolink™, an oxidized raffinose cross-linked hemoglobin-based blood substitute. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 335–51

    Google Scholar 

  51. Fischer SR, Bone HG, Powell WC, et al. Pyridoxalated hemoglobin polyoxyethylene conjugate does not restore hypoxic pulmonary vasoconstriction in ovine sepsis. Crit Care Med 1997; 25(9): 1551–9

    Article  PubMed  CAS  Google Scholar 

  52. Linberg R, Conover CD, Shum KL, et al. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo 1998 Mar–Apr; 12(2): 167–73

    PubMed  CAS  Google Scholar 

  53. Vandegriff KD, McCarthy M, Rohlfs RJ, et al. Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface conjugated. Biophys Chem 1997; 69: 23–30

    Article  PubMed  CAS  Google Scholar 

  54. Lee R, Neya K, Svizzero TA, et al. Limitations on the efficacy of hemoglobin-based oxygen carrying solutions. J Appl Physiol 1995; 79: 236–42

    PubMed  CAS  Google Scholar 

  55. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol-DA as a red cell substitute in acute anemia. N Engl J Med 1986; 314: 1653–6

    Article  PubMed  CAS  Google Scholar 

  56. Flaim SF. Medical and therapeutic applications of perfluorocarbon-based products. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes: basic principles and clinical applications. New York (NY): Marcel Dekker, Inc., 1998: 437–64

  57. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids drugs or miracle solutions? Anesth Analg 1996; 82: 390–405

    PubMed  CAS  Google Scholar 

  58. Ross PE. Brewing blood. Can Somatogen bring its artificial blood to market? The little biotech company faces enormous odds to win the glittering prize. Forbes 1997 Nov 17: 166–7

    Google Scholar 

  59. Burton TM. Pharmacia & Upjohn calls off venture for blood substitute. Wall Street J 1996 Jul 5: B10

    Google Scholar 

  60. Bickell WH, Wall MJ, Pepe PE, et al. Immediate versus delayed resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331: 1105–9

    Article  PubMed  CAS  Google Scholar 

  61. Sloand EM, Pitt E, Klein HG. Safety of the blood supply. JAMA 1995; 274: 1368–73

    Article  PubMed  CAS  Google Scholar 

  62. Manning FJ, Sparacino L, editors. Blood donors and the supply of blood and blood products. Washington (WA): National Academy Press, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood Research Detachment, Walter Reed Army Institute of Research, Washington, DC, 20307-5100, USA

    John R. Hess

Authors
  1. John R. Hess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R. Hess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hess, J.R. Blood Substitutes for Surgery and Trauma. BioDrugs 12, 81–90 (1999). https://doi.org/10.2165/00063030-199912020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199912020-00001

Keywords

Search

Navigation